Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 10:00:04 pm
46.01 USD   -2.75%
2014Amid Alibaba fever, reasons for caution in IPO market
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
47.62(c) 45.71(c) 47.13(c) 47.31(c) 46.01(c) Last
464 479 385 434 372 260 574 979 555 078 Volume
+2.06% -4.01% +3.11% +0.38% -2.75% Change
More quotes
Financials (USD)
Sales 2018 49,7 M
EBIT 2018 -376 M
Net income 2018 -202 M
Finance 2018 285 M
Yield 2018 -
Sales 2019 102 M
EBIT 2019 -357 M
Net income 2019 -356 M
Finance 2019 252 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 41,1x
EV / Sales2019 20,4x
Capitalization 2 327 M
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics... 
More about the company
Surperformance© ratings of Ultragenyx Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on ULTRAGENYX PHARMACEUTICAL
12/07Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (buros..
AQ
12/06Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™..
GL
11/15ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/14ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
11/14ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/12ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/09ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/06ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
11/05ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
11/05ULTRAGENYX : 3Q Earnings Snapshot
AQ
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 70,5 $
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC-0.80%2 327
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
GENMAB3.84%9 952
SAREPTA THERAPEUTICS INC114.81%7 987